MK-1654-007
Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus Disease
Completed
Trial purpose
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT04938830
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
RSV Infection
Age Range
All ages
Sex
Male/Female
Study Details
Current trial Phase
Phase 3
Tests the medicine or vaccine in approximately 1,000 to 5,000 participants. For medicines, participants have the disease or condition the medicine is designed to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 11-30-2021
- Estimated primary completion date 04-28-2025
- Estimated trial completion date 08-01-2025
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.